TCT和HPV基因分型检测技术在宫颈癌筛查中的临床应用  

Clinical application of TCT and HPV genotyping detection technology in screening of cervical cancer

作　　者：陆少颜[1] 伍淑瑶[1] 梁小萍[1] 陈泳言[1] 谭忠伟[1] 彭彧[1] 严秋林[1] 陈敏[1] 

机构地区：[1]广东省江门市妇幼保健院,529000

出　　处：《中国妇幼保健》2011年第11期1710-1711,共2页Maternal and Child Health Care of China

基　　金：江门市科技计划项目〔200976〕

摘　　要：目的:探讨导流杂交基因芯片技术(HybriMax)联合薄层液基细胞学(TCT)在宫颈癌筛查临床应用。方法:2009年1月～2010年3月1 500例患者的宫颈脱落细胞为标本来源,采用薄层液基细胞学技术进行细胞学检查,同时采用导流杂交基因芯片技术进行高危型人乳头瘤病毒分型检测,TCT≥ASCUS或HPV阳性的患者进行阴道镜下活组织病理学检查。结果:1 500例受检者TCT结果异常238例,占15.9%,HPV阳性者316例,占21.1%;CINⅡ以上检测敏感率TCT为75.9%～100.0%、HPV为80.0%～100.0%、TCT联合HPV检测为89.8%～100.0%,TCT联合HPV检测明显优于单次HPV检测或者单次TCT的检查。结论:HPV基因分型(HybriMax)与TCT联合检测时可提高宫颈癌前病变的检出率,是一种高效、便捷的宫颈癌筛查方法。Objective：To explore the clinical application of HybriMax combined with thin-layer liquid-based cytology technology（TCT） in screening of cervical cancer. Methods：The cervical exfoliative cells of 1 500 patients were collected from January 2009 to March 2010,TCT was used for cytological detection,at the same time,HybriMax was used for high risk human papillomavirus（HPV） detection,the patients with TCT≥ASCUS or positive HPV received biopsy and pathological examination under colposcope. Results：Among 1 500 patients,238 patients were found with abnormal TCT results,accounting for 15.9%,316 patients were found with positive HPV,accounting for 21.1%;for the patients with lesions above CINⅡ,the sensitivities of TCT,HPV detection and TCT combined with HPV detection were 75.9%100.0%,80.0%100.0% and 89.8%100.0%,respectively,the sensitivity of TCT combined with HPV detection was superior to those of single HPV detection and single TCT. Conclusion：HybriMax combined with TCT can increase the detection rate of cervical precancerous lesions,which is an effective and convenient screening method of cervical cancer

关 键 词：薄层液基细胞学 人乳头瘤病毒基因分型 宫颈癌筛查 

分 类 号：R737.33[医药卫生—肿瘤]